Drug Profile
ACI 24
Alternative Names: ACI-24; ACI-24.060; Anti-Abeta vaccine - AC immune; Pal1-15 acetate saltLatest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator AC Immune
- Developer AC Immune; University of California, San Diego
- Class Alzheimer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
- Phase I/II Down syndrome
Most Recent Events
- 27 Jun 2023 ACI 24 receives Fast Track designation from the US FDA for Alzheimer's disease
- 27 Jun 2023 US FDA approves IND application to expand ongoing phase Ib/II ABATE trial in Alzheimer’s disease in USA
- 28 Apr 2023 AC Immune plans to file an IND application to expand phase Ib/II ABATE clinical trial in USA, in H1 of 2023